Clene’s CNM-Au8 associated with delay in clinical worsening for ALS patients

Clene and its wholly owned subsidiary Clene Nanomedicine, a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, announced new results from exploratory analyses including delayed time to key clinical progression events in people living with amyotrophic lateral sclerosis – ALS – who were treated with CNM-Au8 in the HEALEY ALS Platform Trial over the 6-months of the double-blind period. New six-month findings from the HEALEY ALS Platform Trial: treatment with CNM-Au8 30mg over 24-weeks was associated with a 74% decreased risk – lower hazard – of the composite endpoint of time to ALS clinical worsening. Living longer, being independent of breathing support, and eating and drinking without a stomach feeding tube is important for ALS patients to lead more independent lives. Treatment with CNM-Au8 was also associated with statistically significant and directional trends across all prespecified time to clinical worsening event analyses: 98% decreased risk of death or permanently assisted ventilation, 95% decreased risk of death, 74% decreased risk of feeding tube placement, 63% decreased risk of assisted ventilation, 84% decreased risk of ALS-related hospitalization, 69% decreased risk of all-cause hospitalization. CNM-Au8 treatment was well-tolerated without significant safety concerns.